Document Detail

Prospective, noninterventional, uncontrolled, open-chart, pharmacoepidemiologic study of prescribing patterns for lipid-lowering drugs at a tertiary care teaching hospital in North India.
MedLine Citation:
PMID:  12581545     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The guidelines for management of dyslipidemia released by the US National Cholesterol Education Program (NCEP) have been questioned for their relevance in the South Asian Indian populations because these populations are reported to have significantly different lipoprotein parameters and atherogenic risk factors than Western populations. OBJECTIVE: The aim of this study was to determine current prescribing patterns for lipid-lowering drugs (LLDs) adopted by physicians in North India. METHODS: This prospective, noninterventional, uncontrolled, open-chart, pharmacoepidemiologic study was conducted from June 2000 to August 2000 at a tertiary care hospital in North India and included 200 dyslipidemic patients. The pattern of prescribing LLDs was recorded, along with the serum levels of lipid parameters-total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and lipoprotein(a) (Lp[a])-at the time of initiating LLD therapy and compared with the 1993 NCEP-II therapeutic guidelines for dyslipidemia management. RESULTS: The mean (SD) levels of lipid parameters in the study population were as follows: TC, 223.2 (21.5) mg/dL; TG, 258.4 (61.3) mg/dL; LDL-C, 131.6 (26.5) mg/dL; HDL-C, 39.8 (8.9) mg/dL; and Lp(a), 44.8 (26.8) mg/dL. The LLDs prescribed were fibrates (53.5%) and statins (46.5%). Forty percent of patients prescribed LLDs did not meet the NCEP-II criteria for initiation of LLD therapy. CONCLUSIONS: Considerable differences in prescribing patterns of LLDs were observed compared with the then-prevalent NCEP-II guidelines. However, due to the abnormally high serum Lp(a) levels present in the average dyslipidemia profile in South Asian Indian populations, this pattern was in accordance with the specific recommendations made for these populations, as well as with the 2001 NCEP-III guidelines.
Pankaj Goyal; Geeta Sharma; Baljinderpal S Bal; Jatinder Singh; Jagjit Singh; Gurpreet Kaur Randhawa; Shaloo Pandhi; Rohit Sharma
Related Documents :
15546905 - Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in commun...
11948055 - Hyperlipidemia prevents the expected reduction of myocardial ischemia on repeated ballo...
6588975 - Treatment of type iii hyperlipoproteinemia with four different treatment regimens.
9113625 - Effect of liposome-encapsulated hemoglobin on triglyceride, total cholesterol, low-dens...
971345 - Incorporation in vitro of 14c-labelled acetate and 32p-labelled phosphate into lipid in...
22806765 - Octreotide alleviates obesity by reducing intestinal glucose absorption and inhibiting ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  24     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2002 Dec 
Date Detail:
Created Date:  2003-02-12     Completed Date:  2003-04-09     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2064-76     Citation Subset:  IM    
Department of Pharmacology, Government Medical College, Amritsar, Punjab, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / therapeutic use*
Cholesterol / blood
Diabetes Complications
Drug Prescriptions / statistics & numerical data*
Drug Utilization
Hospitals, Teaching
Hyperlipidemias / diet therapy,  drug therapy*,  epidemiology
Hypertension / complications
India / epidemiology
Middle Aged
Prospective Studies
Triglycerides / blood
Reg. No./Substance:
0/Antilipemic Agents; 0/Triglycerides; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progressi...
Next Document:  A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of prote...